Have any thoughts about
Seagen Inc?
Write Note

Relative Value

The Relative Value of one SGT stock under the Base Case scenario is 245.18 EUR. Compared to the current market price of 208.6 EUR, Seagen Inc is Undervalued by 15%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

SGT Relative Value
Base Case
245.18 EUR
Undervaluation 15%
Relative Value
Price
S
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
26
vs Industry
Median 3Y
17.4
Median 5Y
17.7
Industry
7.9
Forward
17
vs History
vs Industry
Median 3Y
-53.3
Median 5Y
-53.3
Industry
23.3
Forward
-53.2
vs History
vs Industry
Median 3Y
-73.6
Median 5Y
-74
Industry
22.8
vs History
vs Industry
Median 3Y
-57
Median 5Y
-57
Industry
26.4
vs History
7
vs Industry
Median 3Y
13.4
Median 5Y
10.9
Industry
2.6
vs History
25
vs Industry
Median 3Y
16.8
Median 5Y
16.8
Industry
7.6
Forward
16.5
vs History
17
vs Industry
Median 3Y
21.3
Median 5Y
20.7
Industry
9
vs History
vs Industry
Median 3Y
-57.2
Median 5Y
-57.2
Industry
4.7
Forward
-53.3
vs History
vs Industry
Median 3Y
-51.6
Median 5Y
-51.6
Industry
4.3
Forward
-49.3
vs History
vs Industry
Median 3Y
-71.4
Median 5Y
-71.7
Industry
6.4
vs History
vs Industry
Median 3Y
-55.2
Median 5Y
-55.3
Industry
4.2
vs History
30
vs Industry
Median 3Y
18.3
Median 5Y
18.3
Industry
4.7

Multiples Across Competitors

SGT Competitors Multiples
Seagen Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Seagen Inc
F:SGT
39.3B EUR 18.5 -56.8 -61.1 -55.1
US
Abbvie Inc
NYSE:ABBV
333B USD 6.1 62.9 15.4 23.6
US
Amgen Inc
NASDAQ:AMGN
172.6B USD 5.6 55.1 19.5 35.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
128.7B USD 12.4 -262.7 28 29.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
110.9B USD 8.2 25.7 22.3 24.7
US
Gilead Sciences Inc
NASDAQ:GILD
108.9B USD 3.9 103.4 9.8 12.4
US
Epizyme Inc
F:EPE
94.1B EUR 1 923 -490.7 -534.4 -520.1
AU
CSL Ltd
ASX:CSL
145.8B AUD 6.6 37 22.6 28.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
38B USD 16.2 -521.2 230.2 354.4
KY
Beigene Ltd
SSE:688235
243B CNY 11 -55.6 -34.4 -34.4
NL
argenx SE
NASDAQ:ARGX
32.5B USD 16.7 -117.4 -93.5 -68.1
P/E Multiple
Earnings Growth
US
S
Seagen Inc
F:SGT
Average P/E: 56.8
Negative Multiple: -56.8
N/A
US
Abbvie Inc
NYSE:ABBV
62.9
406%
US
Amgen Inc
NASDAQ:AMGN
55.1
74%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -262.7
38%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
25.7
56%
US
Gilead Sciences Inc
NASDAQ:GILD
103.4
71%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -490.7 N/A
AU
CSL Ltd
ASX:CSL
37
64%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -521.2 N/A
KY
Beigene Ltd
SSE:688235
Negative Multiple: -55.6 N/A
NL
argenx SE
NASDAQ:ARGX
Negative Multiple: -117.4 N/A
EV/EBITDA Multiple
EBITDA Growth
US
S
Seagen Inc
F:SGT
Average EV/EBITDA: 49.7
Negative Multiple: -61.1
N/A
US
Abbvie Inc
NYSE:ABBV
15.4
28%
US
Amgen Inc
NASDAQ:AMGN
19.5
64%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28
37%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
22.3
53%
US
Gilead Sciences Inc
NASDAQ:GILD
9.8
9%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -534.4 N/A
AU
CSL Ltd
ASX:CSL
22.6
42%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
230.2
N/A
KY
Beigene Ltd
SSE:688235
Negative Multiple: -34.4 N/A
NL
argenx SE
NASDAQ:ARGX
Negative Multiple: -93.5 N/A
EV/EBIT Multiple
EBIT Growth
US
S
Seagen Inc
F:SGT
Average EV/EBIT: 72.6
Negative Multiple: -55.1
N/A
US
Abbvie Inc
NYSE:ABBV
23.6
88%
US
Amgen Inc
NASDAQ:AMGN
35.3
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
29.4
44%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
24.7
54%
US
Gilead Sciences Inc
NASDAQ:GILD
12.4
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -520.1 N/A
AU
CSL Ltd
ASX:CSL
28.1
55%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
354.4
N/A
KY
Beigene Ltd
SSE:688235
Negative Multiple: -34.4 N/A
NL
argenx SE
NASDAQ:ARGX
Negative Multiple: -68.1 N/A

See Also

Discover More
Back to Top